UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
April
17, 2009
Date of Report (Date of earliest event reported)
Medicis Pharmaceutical Corporation
(Exact name of registrant as specified in its charter)
|
|
|
|
|
Delaware
|
|
001-14471
|
|
52-1574808 |
(State of Incorporation)
|
|
(Commission File Number)
|
|
(IRS Employer
Identification Number) |
7720 North Dobson Road
Scottsdale, Arizona 85256
(Address of principal executive offices) (Zip Code)
(602) 808-8800
(Registrants telephone number, including area code)
N/A
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the
filing obligation of the registrant under any of the following provisions:
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR
240.14d-2(b))
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR
240.13e-4(c))
Item 8.01 Other Events.
On
April 17, 2009, Medicis Pharmaceutical Corporation (the Company) announced that the
United States Patent and Trademark Office has issued another Notice of Allowance for the Companys
United States patent application directed to SOLODYN® in 90mg tablet form. A press release dated
April 17, 2009 announcing the issuance of the Notice of Allowance is attached as Exhibit 99.1
hereto and is incorporated herein by reference.
Item 9.01 Exhibits.
(d) Exhibits
|
|
|
99.1
|
|
Press Release dated April 17, 2009. |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the
registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly
authorized.
|
|
|
|
|
|
|
|
Date: April 17, 2009 |
By: |
/s/ Jason D. Hanson
|
|
|
|
Jason D. Hanson |
|
|
|
Executive Vice President, General Counsel and Corporate Secretary |
|